Loading
NASDAQIndustrialsAgricultural - Commodities/Milling
Latest quote
$1.84
+$0.03 · +1.66%
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
Regular session
$1.84
+$0.03 · +1.66%
Regular session · ET · Market data may be delayed.
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
Day range
Current $1.84
52-week range
Current $1.84
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
73
Undervalued
Sentiment
38
Bearish
Risk
74
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
Day range
Current $1.84
52-week range
Current $1.84
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 34.51M USD | 25.19M USD | 12.67M USD | 5.5M USD | 2.1M USD |
| Cost of goods sold | 14.03M USD | 11.25M USD | 7.04M USD | 4.28M USD | 1.43M USD |
| Gross profit | 20.48M USD | 13.94M USD | 5.63M USD | 1.22M USD | 670K USD |
| Research and development | 5.31M USD | 4.8M USD | 3.37M USD | 2.31M USD | 4.13M USD |
| Selling, general, and administrative | 19.14M USD | 14.67M USD | 12.08M USD | 9.35M USD | 4.76M USD |
| Operating expenses | 26.05M USD | 20.93M USD | 15.6M USD | 11.83M USD | 9.16M USD |
| Interest income | 54K USD | — | — | — | — |
| Interest expense | 2.72M USD | 1.93M USD | 1.96M USD | 1.4M USD | 805K USD |
| Depreciation and amortization | 1.62M USD | 1.25M USD | 840K USD | 712K USD | 385.58K USD |
| Operating income | −5.58M USD | −6.99M USD | −9.97M USD | −10.61M USD | −8.49M USD |
| Net income | −11.14M USD | −12.91M USD | −12.56M USD | −11.24M USD | −9.83M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.00
171.74% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
